Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Journal article

BACKGROUND: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens. METHODS: We compared rituximab with cyclophosphamide as induction therapy in ANCA-associated vascu...

Expand abstract

Authors: Jones, R; Tervaert, J; Hauser, T; Luqmani, R; Morgan, MD

• Publication status: Published
• Journal: New England journal of medicine
• Volume: 363
• Issue: 3
• Pages: 211-220
• Publication date: 2010-07-01
• DOI: 10.1056/nejmoa0909169
• EISSN: 1533-4406
• ISSN: 0028-4793
• Language: English
• Keywords: Remission Induction; Female; Humans; Incidence; Cyclophosphamide; Immunosuppressive Agents; Antibodies, Monoclonal; Glomerular Filtration Rate; B-Lymphocytes; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Middle Aged; Intention to Treat Analysis; Male; Glucocorticoids; Kidney Diseases; Aged; Infusions, Intravenous; Drug Therapy, Combination; Antibodies, Monoclonal, Murine-Derived; European Vasculitis Study Group; Methylprednisolone